XGPHARM
Home About Us Products Quality Control News Contact
Request a Quote
Quality Control

Setting the standard for pharmaceutical quality

Our quality system protects the safety, efficacy and purity of every active pharmaceutical ingredient we produce, including our flagship Rifampicin and Rifapentine APIs.

Choosing Hebei Xingang Pharmaceutical means partnering with a company where quality control is paramount — backed by GMP certifications, advanced facilities and dedicated expertise.

3 GMP Milestones

Chinese GMP certification in 2004, 2010 and 2015, followed by WHO GMP in 2025.

4 QC Laboratories

Specialised laboratories covering fermentation, synthesis and both factory areas.

100% Commitment

Full alignment with global pharmacopoeia and regulatory expectations.

Our Quality Journey

2004Rifampicin and Rifapentine APIs introduced; first Chinese GMP certification passed.
2010Second domestic GMP certification passed.
2015New-version Chinese GMP certification successfully achieved.
2025WHO expert inspection passed and WHO GMP certificate received.

State-of-the-Art Infrastructure

Fermentation Workshop

Computer temperature control and automatic feeding bring fermentation equipment close to international advanced level.

Extraction Workshop

Continuous improvement of the Rifamycin S sodium extraction process raises both efficiency and product quality.

Synthesis Workshop

Two fully independent lines with separated personnel and material flows avoid any risk of product confusion.

Utilities & Clean Areas

Computer-controlled clean-area pressure differentials, enclosed vacuum feeding and Atlas oil-free screw air compressors.

Four Specialised Laboratories

1. Fermentation Central Control Room

Monitoring and control of fermentation parameters and strain performance.

2. Synthesis Central Control Room

In-process control across both independent synthesis lines.

3. East Factory Area Laboratory

Raw material, intermediate and in-process analytical testing.

4. West Factory Area Central Laboratory

Finished API release testing, stability and method validation.

API Manufacturing Quality Standards

  • Raw Material Inspection — the quality and authenticity of all incoming materials are verified against strict specifications before entering production.
  • In-Process Control — critical parameters are continuously monitored at every stage to prevent deviations and ensure consistency.
  • Finished Product Testing — every batch undergoes a full test programme for identity, purity, potency and safety before release.
  • Stability Studies — ongoing studies under varied temperature and humidity conditions establish shelf life and long-term efficacy.
  • Process & Method Validation — manufacturing processes, equipment and analytical methods are validated to prove robust, reproducible results.
  • Documentation & Traceability — meticulous batch records provide full transparency from raw material to the final customer.

Pharmacopoeia Compliance

Our products meet the latest BP, EP and USP pharmacopoeia standards (and CP where applicable), satisfying the quality requirements of customers worldwide. We welcome customer questionnaires, consultations and on-site or remote audits.

Request our quality documentation

Contact us for specifications, GMP evidence or audit coordination.

Contact Quality Team

Hebei Xingang Pharmaceutical Co., Ltd.. Powered by Blogger.
  • Home
  • About
  • Products
  • Quality control
  • Contact us

Hebei Xingang Pharmaceutical Co., Ltd.

Professional manufacturer of Rifampicin and Rifamycin Derivatives. Rifamycin S Sodium, Rifamycin S, Rifampicin, Rifandine, Rifaximin, Rifampin producer supplier exporter

Home Quality control

Quality control

This page is generated by the site theme. Please open the live page to view the current quality control content.

Home
Subscribe to: Posts ( Atom )

Popular Posts

  • Hebei Xingang Pharmaceutical Co Ltd at CPHI China 2025: Booth W7A15 - Innovating Rifamycin Solutions
    CPHI China 2025: Meet Hebei Xingang Pharmaceutical at Booth W7A15 Event Details: Date:  June 24-26, 2025 Location:  Shanghai New Internation...
  • Hebei Xingang Pharmaceutical's Rifampicin Achieves WHO-PQ and GMP Approval
    Hebei Xingang Pharmaceutical: WHO-PQ & GMP Milestone ...
  • Hebei Xingang Pharmaceutical Co., Ltd.
    This article has been retired. For current company information, product portfolio and GMP certificates, please visit our About and Products...

Labels

  • 2026 global tuberculosis report
  • acceptable intake
  • accuracy
  • ALCOA+
  • all-oral therapy
  • amikacin
  • analytical balance
  • analytical method validation
  • angle of repose
  • anti-tuberculosis intermediates
  • antibody deficiency
  • API impurity limits
  • base patent
  • BDLC
  • BDLLfxC
  • bedaquiline
  • bioavailability
  • Booth W7A15
  • BPaL
  • BPaLC
  • BPaLM
  • breakpoint
  • bulk drug substance
  • calculation rules
  • CD15 expression
  • CD66b expression
  • clofazimine
  • cold chain
  • content uniformity
  • contezolid
  • CPHI China 2025
  • cross-border segmented production
  • D10 D50 D90
  • data integrity
  • delamanid
  • dissolution rate
  • Drug approval
  • drug susceptibility testing
  • drug-resistant TB
  • drug-susceptible TB
  • dry method
  • elemental impurities
  • End TB Strategy
  • endosome
  • fill-finish
  • fluoroquinolone resistance
  • forced degradation
  • four-component architecture
  • freedom to operate
  • GB/T 8170
  • Global health standards
  • GMP
  • Hebei Xingang Pharmaceutical
  • Hebei Xingang Pharmaceutical Co Ltd
  • heteroresistance
  • HPLC method validation
  • ICH Q2(R2)
  • ICH Q9(R1)
  • IGRA testing
  • ionizable lipid
  • isoniazid
  • isoniazid preventive therapy
  • laser diffraction
  • latent TB infection
  • latent tuberculosis infection prevention
  • LC-aNAATs
  • levofloxacin
  • linearity
  • linezolid
  • lipid chemistry
  • lipid nanoparticle
  • marketing authorization holder
  • MDR/RR-TB
  • mic distribution entropy
  • micronization
  • minimum inhibitory concentration
  • moxifloxacin
  • multidrug resistant tuberculosis
  • mutagenic impurities
  • near-point-of-care molecular test
  • neutrophil activation
  • nine-month regimen
  • nitrosamine impurities
  • nontuberculous mycobacterial pulmonary disease
  • NPOC-NAATs
  • obscuration
  • opsonophagocytosis
  • organic impurities
  • patent family
  • peak purity
  • permitted daily exposure
  • pharmaceutical ingredients China
  • Pharmaceutical quality
  • pKa tuning
  • powder particle size distribution
  • pre-XDR-TB
  • precision
  • pretomanid
  • qc laboratory data rounding rules
  • quality agreement
  • quality by design
  • raw data
  • relative standard deviation
  • residual solvents
  • resistance to rifampicin
  • rifabutin based regimens
  • Rifampicin
  • rifampicin preventive treatment
  • rifampicin resistance detection
  • rifampicin resistant tuberculosis
  • rifamycin APIs
  • rifapentine
  • RR/MDR-TB short-course treatment
  • shannon entropy
  • significant figures
  • six-month regimen
  • specification limit
  • specificity
  • sputum pooling strategy
  • surveillance
  • system suitability
  • TB contact screening
  • TB deaths
  • TB diagnostic gap
  • TB disease
  • TB incidence
  • TB mortality
  • TB preventive treatment
  • TB treatment
  • TBST EC test
  • technology transfer
  • threshold of toxicological concern
  • tongue swab TB test
  • tuberculosis
  • tuberculosis diagnosis
  • tuberculosis preventive treatment
  • tuberculosis treatment guidelines
  • weighing precision
  • wet method
  • What is MIC distribution entropy
  • WHO GMP certified
  • WHO market entry
  • WHO tuberculosis diagnosis guidelines
  • WHO-PQ
  • World Health Organization

Blog Archive

  • November 2026 (15)
  • June 2025 (2)
  • March 2025 (1)
  • February 2023 (1)
  • December 2022 (15)
  • November 2022 (29)
  • October 2022 (13)
  • September 2022 (29)
  • August 2022 (32)
  • July 2022 (29)
  • June 2022 (30)
  • May 2022 (30)
  • April 2022 (27)
  • March 2022 (28)
  • February 2022 (20)
  • January 2022 (17)
  • December 2021 (26)
  • November 2021 (26)
  • October 2021 (24)
  • September 2021 (26)
  • August 2021 (23)
  • July 2021 (23)
  • June 2021 (20)
  • May 2021 (4)

My Instagram

Follow me at INSTAGRAM Contact me via EMAIL Follow me at TWITTER Follow me at FACEBOOK Follow me at PINTEREST
Copyright 2025 Hebei Xingang Pharmaceutical Co., Ltd.. Designed by OddThemes | Distributed By Gooyaabi Templates

Hebei Xingang Pharmaceutical Co., Ltd.

Professional manufacturer of Rifampicin and Rifamycin derivatives, supplying GMP-certified APIs and intermediates to formulation partners worldwide.

Zhaoxian Industrial Park, Shijiazhuang, Hebei, China

Explore

  • Home
  • About Us
  • Products
  • Quality Control
  • News
  • Contact Us

Get in Touch

  • Phone: +86-311-80889705
  • Fax: +86-311-84922430
  • Mobile / WhatsApp: +86-13837178289
  • Email: info@xgpharm.cn
  • Email: xgpharm@hotmail.com
  • Web: www.xgpharm.cn
© 2026 Hebei Xingang Pharmaceutical Co., Ltd. All rights reserved. Rifampicin & Rifamycin Series APIs · Established 1996